5 Diagnostics advisory committee members and NICE project team
Diagnostics advisory committee
The diagnostics advisory committee is an independent committee consisting of 22 standing members and additional specialist members. During this assessment the membership of the diagnostics advisory committee changed because some members reached the end of their terms and others were appointed in their place. A full list of the committee members who participated in this assessment appears below.
Standing committee members
Professor Ron Akehurst
Professor in Health Economics, School of Health and Related Research (ScHARR), University of Sheffield
Dr Trevor Cole
Consultant Clinical and Cancer Geneticist, Birmingham Women's Hospital NHS Foundation Trust
Dr Paul Collinson
Consultant Chemical Pathologist, St George's Hospital
Dr Sue Crawford
GP Principal, Chillington Health Centre
Professor Ian A Cree
Senior Clinical Advisor, Warwick Medical School, University Hospitals Coventry and Warwickshire
Professor Erika Denton
National Clinical Director for Diagnostics, NHS England, Honorary Professor of Radiology, University of East Anglia and Norfolk and Norwich University Hospital
Dr Steve Edwards
Head of Health Technology Assessment, BMJ Evidence Centre.
Mr David Evans
Lay representative
Dr Simon Fleming
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Cornwall Hospital
Professor Lisa Hall
Professor of Analytical Biotechnology, University of Cambridge
Professor Noor Kalsheker
Professor of Clinical Chemistry, University of Nottingham
Dr Mark Kroese
Vice Chair, Diagnostics Advisory Committee and Consultant in Public Health Medicine, PHG Foundation, Cambridge and UK Genetic Testing Network
Dr Peter Naylor
GP, Chair Wirral Health Commissioning Consortia
Professor Adrian Newland
Chair, Diagnostics Advisory Committee
Dr Richard Nicholas
Consultant Neurologist; Honorary Senior Lecturer, Heatherwood and Wexham Park Hospitals NHS Foundation Trust
Dr Gail Norbury
Consultant Clinical Scientist, Guy's and St Thomas' NHS Foundation Trust
Ms Margaret Ogden
Lay representative
Dr Diego Ossa
Director of Market Access Europe, Novartis Molecular Diagnostics
Mr Stuart Saw
Head of Financial Strategy London, NHS England
Dr Steve Thomas
Consultant Vascular and Cardiac Radiologist at Sheffield Teaching Hospitals Foundation Trust
Mr Paul Weinberger
CEO, DiaSolve Ltd, London
Mr Christopher Wiltsher
Lay representative
Specialist committee members
Dr Fiona Blackhall
Consultant Medical Oncologist and Honorary Senior Lecturer, Christie Hospital NHS Foundation Trust
Mrs Mandi Elliott
Chemotherapy Nurse Specialist, Queen's Centre for Oncology and Haematology
Mr Tom Haswell
Lay Representative
Mr Paul Roberts
Consultant Cytogeneticist and Interim Head of Department, St James's Hospital
Dr Mark Slade
Consultant Respiratory Physician and Clinical Director, Papworth Hospital NHS Foundation
Dr Phillipe Taniere
Consultant Histopathologist, Queen Elizabeth Hospital Birmingham
NICE project team
Each diagnostics assessment is assigned to a team consisting of a Technical Analyst (who acts as the topic lead), a Technical Adviser and a Project Manager.
Frances Nixon and Farouk Saeed
Topic Leads
Pall Jonsson
Technical Adviser
Robert Fernley
Project Manager
Sources of evidence considered by the committee
The diagnostics assessment report was prepared by Kleijnen Systematic Reviews Ltd in collaboration with Erasmus University Rotterdam and Maastricht University.
-
Westwood ME, Joore MA, Whiting P et al. Epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: a systematic review and cost-effectiveness analysis. (January 2013)
Registered stakeholders
The following organisations accepted the invitation to participate in this assessment as registered stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.
Manufacturers/sponsors:
-
Roche Molecular Systems, Inc.
-
Qiagen Ltd.
Professional/specialist and patient/carer groups:
-
All Wales Molecular Genetics Lab
-
AstraZeneca
-
Boehringer Ingelheim Limited
-
Bristol Genetics Laboratory
-
British Thoracic Oncology Group (BTOG)
-
Cancer Research UK
-
Coventry and Warwickshire Pathology Services
-
Department of Molecular Haematology, Oxford University Hospitals Trust
-
Edinburgh Cancer Centre
-
European Molecular Genetics Quality Network
-
Guy's and St. Thomas' NHS Foundation Trust
-
Leeds Teaching Hospital
-
The Lothian University Hospitals
-
NCRI Clinical Studies Group/Royal College of Physicians/Royal College of Radiologists/Joint Collegiate Council on Oncology/Association of Cancer Physicians
-
New Gene Ltd
-
NHS Grampian
-
NHS Greater Glasgow and Clyde
-
Royal Devon and Exeter NHS Trust
-
Sheffield Diagnostics Genetics Service
-
St James's Hospital
-
St Mary's Hospital
-
UCL Advanced Diagnostics
-
UK NEQAS (Edinburgh)
-
United Lincolnshire Hospitals NHS Trust
-
University College London Hospital and MRC Clinical Trials Unit
-
University Hospitals Birmingham NHS